Martin Balcaitis is a health and wellness exec who knows about life on the other side. For the first 15 years of his career, ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...

What Hims & Hers stock could be witnessing now is a short-squeeze. As its stock began rising sharply, short-sellers move to get out. So over the past week, we’ve seen shares surge 60%. In midday ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

With today’s sweetener market evolving rapidly, experts highlight how natural sweetener solutions are helping beverage-makers ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...